EUVIMEDEUVIMED entdecken
Open Access

Prognostic impact of monosomy 13 and deletion of 13q in multiple myeloma patients undergoing upfront autologous transplantation

Damian M Mikulski iD, Curtis Marcoux, Mark R Tanner, Qaiser Bashir, Samer Srour iD, Neeraj Saini, Paul Lin, Jeremy Ramdial iD, Yago Nieto iD, Guilin Tang iD, Yosra Aljawai iD, Hans C Lee iD und 8 weitere

British Journal of Haematology · 2026

DOI: 10.1111/bjh.70694 ↗

Kurz gefasst

Fachartikel in der Zeitschrift British Journal of Haematology, 2026. Verfasst von Damian M Mikulski und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA. Hauptthemen laut MEDLINE: Multiple Myeloma, Chromosome Deletion, Hematopoietic Stem Cell Transplantation, Chromosome Disorders. Die Arbeit nennt 40 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, Paula and Rodger Riney Foundation, Dr. Miriam and Sheldon G. Adelson Medical Research Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Deletion (13q)/monosomy 13 (del[13q]/−13) is common in multiple myeloma (MM), but its independent prognostic value remains unclear, particularly in patients treated with modern therapy and upfront autologous haematopoietic stem cell transplantation (autoHSCT). This study aimed to assess its impact on progression‐free survival (PFS) and overall survival (OS), and to evaluate its prognostic impact in the context of established high‐risk cytogenetic abnormalities (HRCA). We conducted a retrospective, single‐centre study of MM patients undergoing autoHSCT between 2010 and 2021 with available fluorescence in situ hybridization results. Among 1680 patients, del(13q)/−13 was identified in 591 (35.2%). Compared with patients without HRCA or del(13q)/−13, isolated del(13q)/−13 was associated with shorter median PFS (37.3 vs. 64.6 months) and OS (105.4 vs. 131.0 months). Patients with concurrent HRCA and del(13q)/−13 had the poorest outcomes, with median PFS and OS of 33.9 and 81.6 months, respectively. Multivariable Cox regression confirmed that isolated/non‐HRCA‐associated del(13q)/−13, was independently associated with inferior PFS (hazard ratio [HR] 1.36, 95% confidence interval [CI]: 1.17–1.58, p = 0.0001) and OS (HR 1.49, 95% CI: 1.21–1.84, p = 0.0002). Del(13q)/−13 is independently associated with inferior PFS and OS in MM patients undergoing autoHSCT, with an additive adverse effect when co‐occurring with HRCA.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Multiple MyelomaChromosome DeletionHematopoietic Stem Cell TransplantationChromosome DisordersHumansChromosomes, Human, Pair 13Transplantation, AutologousPrognosisRetrospective StudiesFemaleMaleMiddle AgedAgedAdult

Stichwörter der Autor:innen

autologous haematopoietic cell transplantationdeletion 13qhigh‐risk cytogeneticsmonosomy 13multiple myeloma

Autor:innen und Institutionen

  • Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Department of Biostatistics and Translational Medicine, Medical University of Lodz, Lodz, Poland.
  • Division of Hematology, Dalhousie University, Halifax, Nova Scotia, Canada.
  • Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

ORCID-Profile: Damian M Mikulski, Samer Srour, Jeremy Ramdial, Yago Nieto, Guilin Tang, Yosra Aljawai, Hans C Lee, Sheeba K Thomas, Robert Z Orlowski, Oren Pasvolsky

Förderung

  • NCI NIH HHS
  • Paula and Rodger Riney Foundation
  • Dr. Miriam and Sheldon G. Adelson Medical Research Foundation
  • Narodowa Agencja Wymiany Akademickiej
  • National Cancer Institute

Zitieren

APA

Mikulski, D. M., Marcoux, C., Tanner, M. R., Bashir, Q., Srour, S., Saini, N., Lin, P., Ramdial, J., Nieto, Y., Tang, G., Aljawai, Y., Lee, H. C., Patel, K. K., Kebriaei, P., Thomas, S. K., Orlowski, R. Z., Champlin, R. E., Shpall, E. J., Qazilbash, M. H., & Pasvolsky, O. (2026). Prognostic impact of monosomy 13 and deletion of 13q in multiple myeloma patients undergoing upfront autologous transplantation. British Journal of Haematology. https://doi.org/10.1111/bjh.70694

Vancouver

Mikulski DM, Marcoux C, Tanner MR, Bashir Q, Srour S, Saini N, et al. Prognostic impact of monosomy 13 and deletion of 13q in multiple myeloma patients undergoing upfront autologous transplantation. British Journal of Haematology. 2026. doi:10.1111/bjh.70694

BibTeX
@article{Mikulski2026,
  author = {Mikulski, Damian M and Marcoux, Curtis and Tanner, Mark R and Bashir, Qaiser and Srour, Samer and Saini, Neeraj and Lin, Paul and Ramdial, Jeremy and Nieto, Yago and Tang, Guilin and Aljawai, Yosra and Lee, Hans C and Patel, Krina K and Kebriaei, Partow and Thomas, Sheeba K and Orlowski, Robert Z and Champlin, Richard E and Shpall, Elizabeth J and Qazilbash, Muzaffar H and Pasvolsky, Oren},
  title = {Prognostic impact of monosomy 13 and deletion of 13q in multiple myeloma patients undergoing upfront autologous transplantation},
  journal = {British Journal of Haematology},
  year = {2026},
  doi = {10.1111/bjh.70694}
}
Kostenlos starten →